Literature DB >> 19557545

Autopsy case of Gaucher disease type I in a patient on enzyme replacement therapy. Comments on the dynamics of persistent storage process.

H Hůlková1, J Ledvinová, H Poupetová, A Kohout, V Malinová, M Elleder.   

Abstract

We report a female patient with Gaucher disease (GD) type I on ERT (imiglucerase) for 5 years, which led to a significant general improvement. Aged 59 years she underwent an episode of altitude sickness followed by sepsis, disseminated intravascular coagulation, and multiorgan failure. She succumbed to a cerebral haemorrhage. Autopsy revealed liver cholestatic cirrhosis and multifocal liver carcinoma with immunophenotype compatible with cholangiocarcinoma. Analysis of the storage process revealed its absence or very low levels in the majority of liver and spleen macrophages. Gaucher cells (GCs) were seen only as occasional aggregates of various sizes in these organs. GCs were seen also in the leptomeninx of the cerebellum and as infrequent perivascular clusters in both the grey and white cerebral matters. Bone marrow was heavily infiltrated with GCs, especially in the adipocyte-rich part. GCs in this location displayed varied degrees of cytoplasmic vacuolation unrelated to the lysosomal compartment, caused by droplets of triglyceride, and interpreted as due to resorption of fragments of altered white adipocytes. All these observations point to the relative efficacy of ERT in covering the standard substrate load, which should not be exceeded as it would lead to the evolution of mature GCs. The results are discussed in relation to our recently published hypothesis on GD cell pathology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19557545     DOI: 10.1007/s10545-009-1178-9

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  22 in total

1.  Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy.

Authors:  Z Erjavec; C E Hollak; E G de Vries
Journal:  Ann Oncol       Date:  1999-02       Impact factor: 32.976

2.  Abdominal ultrasound findings mimicking hematological malignancies in a study of 218 Gaucher patients.

Authors:  O Neudorfer; I Hadas-Halpern; D Elstein; A Abrahamov; A Zimran
Journal:  Am J Hematol       Date:  1997-05       Impact factor: 10.047

3.  Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease.

Authors:  P Leinekugel; S Michel; E Conzelmann; K Sandhoff
Journal:  Hum Genet       Date:  1992-03       Impact factor: 4.132

4.  Determination of protein: a modification of the Lowry method that gives a linear photometric response.

Authors:  E F Hartree
Journal:  Anal Biochem       Date:  1972-08       Impact factor: 3.365

5.  Protein determination in membrane and lipoprotein samples: manual and automated procedures.

Authors:  M A Markwell; S M Haas; N E Tolbert; L L Bieber
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

6.  Brain glucocerebrosidase in Gaucher's disease.

Authors:  L B Daniels; P J Coyle; R H Glew; N S Radin; R S Labow
Journal:  Arch Neurol       Date:  1982-09

7.  Increased incidence of cancer in adult Gaucher disease in Western Europe.

Authors:  M de Fost; S Vom Dahl; G J Weverling; N Brill; S Brett; D Häussinger; C E M Hollak
Journal:  Blood Cells Mol Dis       Date:  2005-10-24       Impact factor: 3.039

8.  Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease.

Authors:  Patrick B Deegan; Mary Teresa Moran; Ian McFarlane; J Paul Schofield; Rolf G Boot; Johannes M F G Aerts; Timothy M Cox
Journal:  Blood Cells Mol Dis       Date:  2005 Sep-Oct       Impact factor: 3.039

9.  [Coincidence of Gaucher disease with primary hepatocellular carcinoma].

Authors:  C M Breiden-Langen; R Büchsel; H J Brambs; M Oehlert; S Matern
Journal:  Leber Magen Darm       Date:  1991-05

10.  Lipolysis of serum-activated triacylglycerol at the surface of J774.1 macrophages. A biochemical--electron-microscopic study.

Authors:  E J Blanchette-Mackie; T Briggs; S S Chernick; R O Scow
Journal:  Cell Tissue Res       Date:  1986       Impact factor: 5.249

View more
  7 in total

1.  Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.

Authors:  Sarah M Lo; Philip Stein; Sean Mullaly; Michael Bar; Dhanpat Jain; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

Review 2.  Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment.

Authors:  Siavash Piran; Dominick Amato
Journal:  J Inherit Metab Dis       Date:  2010-03-25       Impact factor: 4.982

Review 3.  Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism.

Authors:  Makaila L Furderer; Ellen Hertz; Grisel J Lopez; Ellen Sidransky
Journal:  Int J Mol Sci       Date:  2022-05-23       Impact factor: 6.208

Review 4.  Treatment of lysosomal storage disorders: successes and challenges.

Authors:  Carla E M Hollak; Frits A Wijburg
Journal:  J Inherit Metab Dis       Date:  2014-05-13       Impact factor: 4.982

Review 5.  Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism.

Authors:  Pramod K Mistry; Tamar Taddei; Stephan vom Dahl; Barry E Rosenbloom
Journal:  Crit Rev Oncog       Date:  2013

6.  Adipocytes participate in storage in α-galactosidase deficiency (Fabry disease).

Authors:  Helena Hůlková; Milan Elleder
Journal:  J Inherit Metab Dis       Date:  2010-07-14       Impact factor: 4.982

7.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.